IN2014DN07812A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN07812A IN2014DN07812A IN7812DEN2014A IN2014DN07812A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A IN 7812DEN2014 A IN7812DEN2014 A IN 7812DEN2014A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A
- Authority
- IN
- India
- Prior art keywords
- reprogramming
- methods
- marks
- epigenetic
- mark readers
- Prior art date
Links
- 230000008672 reprogramming Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001973 epigenetic effect Effects 0.000 abstract 2
- 102100032920 Chromobox protein homolog 2 Human genes 0.000 abstract 1
- 101000797586 Homo sapiens Chromobox protein homolog 2 Proteins 0.000 abstract 1
- 101000934489 Homo sapiens Nucleosome-remodeling factor subunit BPTF Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100025062 Nucleosome-remodeling factor subunit BPTF Human genes 0.000 abstract 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/64—Screening of libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Computing Systems (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Library & Information Science (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603650P | 2012-02-27 | 2012-02-27 | |
| US201261637282P | 2012-04-24 | 2012-04-24 | |
| PCT/CA2013/050145 WO2013127011A1 (en) | 2012-02-27 | 2013-02-27 | Reprogramming effector protein interactions to correct epigenetic defects in cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07812A true IN2014DN07812A (OSRAM) | 2015-05-15 |
Family
ID=49081499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7812DEN2014 IN2014DN07812A (OSRAM) | 2012-02-27 | 2013-02-27 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9552457B2 (OSRAM) |
| EP (1) | EP2819662B1 (OSRAM) |
| JP (1) | JP6137703B2 (OSRAM) |
| KR (1) | KR102149860B1 (OSRAM) |
| CN (1) | CN104136020B (OSRAM) |
| AU (1) | AU2013225592B2 (OSRAM) |
| BR (1) | BR112014021201B1 (OSRAM) |
| CA (1) | CA2865675C (OSRAM) |
| IN (1) | IN2014DN07812A (OSRAM) |
| RU (1) | RU2637441C2 (OSRAM) |
| WO (1) | WO2013127011A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ712300A (en) * | 2013-03-15 | 2020-07-31 | Sutter West Bay Hospitals | Falz for use as a target for therapies to treat cancer |
| AU2014316783A1 (en) * | 2013-09-09 | 2016-04-28 | Glionova Ab | Compounds and use for treating cancer |
| EP3064205A1 (en) * | 2015-03-06 | 2016-09-07 | Glionova AB | Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol |
| US20180223368A1 (en) * | 2015-03-18 | 2018-08-09 | Memorial Sloan Ketteting Cancer Center | Methods for diagnosing and treating follicular lymphoma |
| JP6862418B2 (ja) | 2015-07-31 | 2021-04-21 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | センサ、カートリッジ、および薬物送達デバイス |
| WO2019084452A1 (en) * | 2017-10-27 | 2019-05-02 | Transfusion Health, Llc | COMPOSITIONS AND METHODS FOR PRODUCING EXPANDED HEMATOPOIETIC STEM CELLS USING FLUORENE DERIVATIVES |
| US20230395185A1 (en) * | 2020-10-14 | 2023-12-07 | The Regents Of The University Of California | Systems for and methods of determining protein-protein interaction |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE603039A (OSRAM) | 1960-04-26 | |||
| GB1120461A (en) * | 1964-07-06 | 1968-07-17 | Manuf Prod Pharma | Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide |
| US3622580A (en) | 1969-03-25 | 1971-11-23 | Smith Kline French Lab | Piperazino-acetylamino-9-fluorenones and-anthraquinones |
| LU85246A1 (fr) | 1984-03-13 | 1985-10-14 | R L Galephar Sa | 2-(aminoalkyl)acrylophenones,leur preparation et leur utilisation |
| US5501959A (en) | 1989-01-17 | 1996-03-26 | Alamar Biosciences Laboratory, Inc. | Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents |
| EP1108055A1 (en) * | 1998-08-25 | 2001-06-20 | The Scripps Research Institute | Methods and systems for predicting protein function |
| US7928218B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
| EP2027087A2 (en) * | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
| WO2009015283A2 (en) | 2007-07-24 | 2009-01-29 | President And Fellows Of Harvard College | Bhc80 - histone complexes and uses thereof |
| JP2012503651A (ja) | 2008-09-26 | 2012-02-09 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | ３−デアザネプラノシン誘導体 |
| WO2010045199A2 (en) | 2008-10-13 | 2010-04-22 | University Of South Florida | Method of modulating ship activity |
| GB0822248D0 (en) | 2008-12-05 | 2009-01-14 | Medical Res Council | Crystal meths |
| WO2010094009A2 (en) | 2009-02-13 | 2010-08-19 | Children's Hospital Medical Center | Methods and compositions for the treatment of ras associated disorders |
| EP2461806A4 (en) | 2009-07-31 | 2012-12-26 | Us Health | SMALL ANTIANGIOGENIC MOLECULES AND METHOD OF USE THEREOF |
| US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| DK2571503T3 (en) | 2010-05-14 | 2015-04-20 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| US20140066410A1 (en) | 2011-02-23 | 2014-03-06 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
| WO2012123119A1 (en) | 2011-03-17 | 2012-09-20 | Cellzome Ag | Methods for the identification and characterization of proteins interacting with histone tails and of compounds interacting with said proteins |
| WO2013059944A1 (en) | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
-
2013
- 2013-02-27 IN IN7812DEN2014 patent/IN2014DN07812A/en unknown
- 2013-02-27 CA CA2865675A patent/CA2865675C/en active Active
- 2013-02-27 US US14/381,588 patent/US9552457B2/en not_active Expired - Fee Related
- 2013-02-27 BR BR112014021201-5A patent/BR112014021201B1/pt not_active IP Right Cessation
- 2013-02-27 JP JP2014557953A patent/JP6137703B2/ja not_active Expired - Fee Related
- 2013-02-27 WO PCT/CA2013/050145 patent/WO2013127011A1/en active Application Filing
- 2013-02-27 AU AU2013225592A patent/AU2013225592B2/en not_active Ceased
- 2013-02-27 EP EP13754077.9A patent/EP2819662B1/en active Active
- 2013-02-27 KR KR1020147027072A patent/KR102149860B1/ko not_active Expired - Fee Related
- 2013-02-27 RU RU2014138543A patent/RU2637441C2/ru active
- 2013-02-27 CN CN201380011304.1A patent/CN104136020B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865675A1 (en) | 2013-09-06 |
| KR20140132382A (ko) | 2014-11-17 |
| RU2014138543A (ru) | 2016-04-20 |
| CA2865675C (en) | 2023-02-28 |
| EP2819662B1 (en) | 2019-04-10 |
| US9552457B2 (en) | 2017-01-24 |
| RU2637441C2 (ru) | 2017-12-04 |
| EP2819662A4 (en) | 2016-03-23 |
| EP2819662A1 (en) | 2015-01-07 |
| BR112014021201B1 (pt) | 2023-01-24 |
| CN104136020A (zh) | 2014-11-05 |
| JP2015515448A (ja) | 2015-05-28 |
| AU2013225592A1 (en) | 2014-10-09 |
| BR112014021201A2 (pt) | 2021-06-08 |
| WO2013127011A1 (en) | 2013-09-06 |
| US20150154345A1 (en) | 2015-06-04 |
| AU2013225592B2 (en) | 2017-11-09 |
| JP6137703B2 (ja) | 2017-05-31 |
| CN104136020B (zh) | 2018-08-28 |
| AU2013225592A2 (en) | 2014-10-09 |
| KR102149860B1 (ko) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07812A (OSRAM) | ||
| BR112015020650A2 (pt) | inibidores de histona demetilases | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| BR112015005227A2 (pt) | inibidores de glicosilceramida sintase | |
| CR20140537A (es) | Compuesto heterocíclico nitrogenado | |
| PH12013500258B1 (en) | Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds | |
| MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
| WO2011038210A3 (en) | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity | |
| BR112016002069A2 (pt) | novo composto de pirimidina fusionada ou sal deste | |
| MX384556B (es) | Cateter con marcas para facilitar alineacion | |
| TN2013000227A1 (en) | Use of sigma ligands in bone cancer pain | |
| PH12012501402A1 (en) | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease | |
| NZ627480A (en) | Inhibitors of iap | |
| GB2514714A (en) | Apparatuses, methods, and systems for the identification and treatment of pulmonary tissue | |
| MX354598B (es) | Uso de neuregulina para tratar lesion de nervio periferico. | |
| MX2015013936A (es) | Compuestos de pirimidina condensada sustituida. | |
| EA201391304A1 (ru) | 2,4-замещенные пиримидиндиамины для применения при дискоидной волчанке | |
| BR112015021324A2 (pt) | derivados de 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de atividade de quinase | |
| IN2014DN09584A (OSRAM) | ||
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| TN2015000020A1 (en) | Molecular markers and methods for early sex determination in date palms | |
| MX2018010829A (es) | Inductores de molécula pequeña de especies de oxígeno reactivo e inhibidores de la actividad mitocondrial. | |
| WO2011103028A3 (en) | Compositions and methods for inhibiting mmset | |
| CL2015003267A1 (es) | Tratamiento eficaz de nsclc y marcador clínico predictivo de la respuesta de un tumor a un tratamiento. |